Avenzo Therapeutics raised $150M in a Series A-1 financing led by New Enterprise Associates (NEA), Deep Track Capital, Sofinnova Investments, and Sands Capital to advance emerging oncology pipeline.
Avenzo Therapeutics raised $150M in a Series A-1 financing led by New Enterprise Associates (NEA), Deep Track Capital, Sofinnova Investments, and Sands Capital to advance emerging oncology pipeline.
03/26/24, 12:04 PM
Location
san diegoMoney raised
$150 million
Industry
biotechnology
Round Type
series a
Investors
Surveyor Capital (A Citadel Company), Lilly Asia Ventures, Sr One, Foresite Capital, Orbi Med, Quan Capital, Delos Capital, Tf Capital, Ince Capital, Sands Capital, Sofinnova Investments, Deep Track Capital, New Enterprise Associates (Nea)
Avenzo Therapeutics, Inc. announced an oversubscribed $150 million Series A-1 financing, bringing the total capital raised since the company’s founding to $347 million. The financing round includes nine new investors and was led by New Enterprise Associates (NEA), Deep Track Capital, Sofinnova Investments, and Sands Capital. The proceeds from the financing will be used to advance Avenzo’s emerging oncology pipeline, particularly the potentially best-in-class cyclin-dependent kinase 2 (CDK2) selective inhibitor AVZO-021.
Company Info
Location
9171 towne centre drive, suite 380
san diego, california, united states
Additional Info
Avenzo Therapeutics is a clinical-stage biotechnology company focused on developing the next generation of oncology therapies for patients. The company’s lead drug candidate, AVZO-021, is a novel, highly potent and selective inhibitor of CDK2, a key enzyme involved in cell cycle regulation. AVZO-021 is being studied in a Phase 1 study in the U.S. for the treatment of advanced solid tumors. Avenzo is headquartered in San Diego, California.